OCRELIZUMAB (Ocrevus) prior authorization at Geisinger Health Plan
Submission criteria, P2P prep, and appeal path if denied — for prescribers and PA staff
Geisinger Health Plan requires CD20-directed Cytolytic Antibody prior-authorization documentation for OCRELIZUMAB (Ocrevus): a diagnosis with ICD-10 code, documented step-therapy history, and prescriber attestation of medical necessity. Standard PA decisions return in 30 days; if denied, prescribers and members have 180 days to appeal.
The PA criteria you'll need to meet
Geisinger Health Plan reviews OCRELIZUMAB (Ocrevus) prior authorizations against its medical policy for CD20-directed Cytolytic Antibody. Geisinger Health Plan-specific context: Integrated payer-provider system in central/northeast Pennsylvania (~600K members). Acquired by Kaiser-affiliated Risant Health in March 2024 — operational integration ongoing. PA Insurance Department oversight. Strong MA presence in service area.
Documentation packet checklist
- Chart note with diagnosis (ICD-10 code) and clinical severity markers
- Documented failure of, contraindication to, or intolerance of step-therapy alternatives in CD20-directed Cytolytic Antibody
- Prior treatment history including dosing, duration, and reason for discontinuation
- Relevant labs, imaging, or assessment scores supporting medical necessity
- Prescriber attestation linking the FDA-approved indication to the patient's presentation
- Geisinger Health Plan's medical policy URL referenced in the cover letter
Geisinger Health Plan's common denial patterns
Pre-empting these patterns in the initial submission cuts rework and shortens time-to-approval:
- Narrow-network denials outside Geisinger system
- Specialty referral coordination
- Medicare Advantage step therapy on Part B drugs
- Out-of-network non-emergency
OCRELIZUMAB (Ocrevus)-specific denial patterns and context
Across payers (not just Geisinger Health Plan), OCRELIZUMAB (Ocrevus)draws a distinct set of denial reasons rooted in the drug's label, REMS, and competitive landscape:
- Site-of-care reduction (home infusion vs hospital)
- Step therapy
Brand: Ocrevus. First FDA-approved DMT for primary progressive MS.
Manufacturer patient-assistance program: Genentech Patient Foundation — relevant when a Geisinger Health Plan denial sticks and the patient needs bridge access while appealing.
If the PA is denied
Geisinger Health Plan gives prescribers and members 180 days to file an internal appeal. Standard appeal decisions return within 30 days. Submit through the provider portal (https://www.geisinger.org/health-plan/providers) with the same packet plus a peer-reviewed citation supporting OCRELIZUMAB (Ocrevus)for the patient's indication.
Helping a patient appeal the denial directly? See the consumer guide: How to appeal a Geisinger Health Plan denial on DenialHelp.
Contact Geisinger Health Plan
- Provider portal: https://www.geisinger.org/health-plan/providers
Frequently asked questions
What documentation does Geisinger Health Plan need for OCRELIZUMAB (Ocrevus) prior auth?
Geisinger Health Plan's typical PA packet for OCRELIZUMAB (Ocrevus): (1) chart note documenting the indication and prior-treatment failures, (2) supporting lab/imaging where indicated, (3) prescriber attestation that step-therapy alternatives were tried or contraindicated, (4) FDA-approved indication mapped to ICD-10 diagnosis. For CD20-directed Cytolytic Antibody, expect clinical-criteria documentation specific to this class.
What's the turnaround time at Geisinger Health Plan?
Standard OCRELIZUMAB (Ocrevus) PA decisions at Geisinger Health Plan: 30 days. Urgent / expedited (member's life or function at risk): 72 hours under 45 CFR §147.136.
What does Geisinger Health Plan most often reject OCRELIZUMAB (Ocrevus) for?
Across Geisinger Health Plan's book the common rejection patterns include: Narrow-network denials outside Geisinger system; Specialty referral coordination; Medicare Advantage step therapy on Part B drugs. For OCRELIZUMAB (Ocrevus) specifically, expect step-therapy challenges and indication-restriction reviews when the use is at the edge of the FDA label or off-label.
How do I prep for a peer-to-peer with Geisinger Health Plan on OCRELIZUMAB (Ocrevus)?
Lead with the FDA-approved indication and the specific clinical criteria the policy lists. Have the patient's chart open, document number, and policy URL on screen. State your name and credentials, the policy number, the indication, and the documented failures of step-therapy alternatives. Keep notes — if the P2P reviewer overturns, get the decision in writing.
Related PA criteria
Generate the OCRELIZUMAB (Ocrevus) PA packet
Open ApprovalHelp — generate a OCRELIZUMAB (Ocrevus) prior-auth packet tailored to Geisinger Health Plan's criteria, with prescriber attestation and step-therapy documentation pre-filled.
Get started →Contact: hello@approvalhelp.com